Study Microvascular outcome Relative RR Absolute RR NNT p-value
FIELD [41]
[N=9,795]
First laser treatment for retinopathy 31% 1.5% 67 0.002
FIELD substudy[41]
[N=1,012]
i) DR progression, i.e. ≥2 steps of the ETDRS,macular edema or laser treatment¬†
ii) ≥2 steps of the ETDRS
All patients
Pre-existing retinopathy
No pre-existing retinopathy
  31%


22%
79%
2.6%
5.0%


2.7%
11.5%
0.3%
20


37
9
333
0.022


0.19
0.004*
0.87*
ACCORD-EYE [3]
[N= 1,593]
DR progression, i.e. ≥3 steps of the ETDRS or proliferative DR requiring laser therapy or vitrectomy 40% 3.7% 27 0.006
*treatment versus retinopathy status interaction, p=0.019; NNT number needed to treat = 1/absolute risk reduction; RR risk reduction; ETDRS Early Treatment Diabetic Retinopathy Study scale; FIELD: Fenofibrate Intervention and Event Lowering in Diabetes; ACCORD: Action to Control Cardiovascular Risk in Diabetes
Table 3: Effects of fenofibrate on Diabetic Retinopathy (DR) progression: Summary of results from the FIELD and ACCORD-Eye studies [13,41].